The University of Michigan announces that it will soon be conducting Phase III trials, by the name ‘AZ1222 COVID-19 Vaccine Study’, on a COVID-19 virus vaccine formulated by the pharmaceutical institution AstraZeneca.
More About AstraZeneca
AstraZeneca is a multinational pharmaceutical firm specializing in medical products related to Abdominal Infection, Cancer, Heart Diseases, Inflammation, Respiratory Diseases, and vice versa.
AstraZeneca was established in 1999 as a merger between the British Zeneca Group and the Swedish Astra AB with the headquarters in Cambridge, England.
While the Astra shareholders hold 46.5% of the shares, 53.5% of the shares are acquired by the Zeneca shareholders.
AstraZeneca’s contribution to the Research for Developing a Vaccine
AstraZeneca has played a vital role in the United States’ battle against COVID-19. It began its research for a vaccine on attaining approval from the University of Oxford. The conclusions from the Phase I and Phase II trials, published in The Lancet Journal, exhibited favorable results.
In its first and second trials, the vaccine showed a four-fold rise in the antibodies produced as a defense against COVID-19. It significantly enriched the body’s immune responses towards the COVID-19 virus in approximately 95% of the patients.
Besides the enhanced immunity and a better recovery rate, the vaccine also contributed to the growth in the T-cells within fourteen days of injecting and which was maintained throughout two months.
AstraZeneca’s Deal with Michigan Medicine for the Phase III Trials
Formerly recognized as the University of Michigan Health System, Michigan Medicine is the University of Michigan’s academic medical center. Astra Zeneca has collaborated with Michigan Medicine for the Phase III trials of its Investigational Vaccine.
The study aims at researching the working of the investigational vaccine and the precautions required while administering it to the COVID-19 patients.
The survey will be conducted on about 30,000 subjects, and immediate recruitment will commence promptly. Operation Warp Speed, a coalition under the United States Department of Health and Human Services, is funding these studies.
AstraZeneca has mediated a deal with several countries regarding the manufacturing and distribution of about 2 billion Vaccine units.
Some of the institutions that are a part of this deal are the Coalition for Epidemic Preparedness Innovations, the Europian Union, Gavi, R-Pharm in Russia, the Serum Institute of India, SK Biopharmaceuticals in the Republic of Korea, United Kingdom, the United States, and Vaccine Alliance.
As the investigational vaccine trials are being prepared for by Michigan Medicine, AstraZeneca has pledged to not profit from the produce and supply of the COVID-19 vaccine.
Stay Safe. Stay Tuned. Stay Safe.